|Brand name(s), other common name(s)||Kyprolis®|
|Drug type||Proteasome inhibitor|
|How the drug is given||Intravenously (IV)|
Indications and Usage
Carfilzomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. It is also indicated as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Side effects needing medical attention
Fatigue; anemia; nausea; low platelet counts; breathlessness; diarrhea; fever; cardiac arrest and other cardiac failure events; pulmonary hypertension; pulmonary complications; liver damage and liver failure; infusion reactions including fever, chills, joint pain, muscle pain, facial flushing, facial edema, vomiting, weakness, shortness of breath, hypotension, fainting, chest tightness, chest pain.